Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

BG-P-TAT, novel dual targeting agent with promising efficacy in models of neuroblastoma

Sep. 18, 2020

New CDK2/cyclin E inhibitors patented by Incyte

Sep. 18, 2020

Synthetic lethal approach for some breast, brain cancers

Sep. 18, 2020

Bio-Path begins phase I study of BP-1002 in advanced lymphoid malignancies

Sep. 18, 2020

Ferro Therapeutics patents new GPX4 inhibitors

Sep. 17, 2020

Chinese researchers present exportin-1 receptor antagonists

Sep. 17, 2020

Chaluesheng Medical Technology divulges RET inhibitors

Sep. 17, 2020

AstraZeneca discloses KRAS mutant inhibitors

Sep. 17, 2020

Interim results from ongoing phase Ib/II study of cavrotolimod

Sep. 17, 2020

Enrollment initiates in first-in-human study of ONC-206

Sep. 17, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...